Pharmacy and Therapeutics Committee Approvals, June 2008

P&T Date: June 3, 2008

<table>
<tr><th>AGENDA ITEM</th><th>P&T COMMITTEE DECISION</th><th>COMMENTS</th></tr>
<tr><td>• PALIPERIDONE EXTENDED RELEASE (INVEGA®)</td><td>NOT ADDED TO FORMULARY

AUTOMATIC SUBSTITUTION OF PALIPERIDONE TO RISPERIDONE</td><td>• Indication: Treatment of acute and maintenance treatment of schizophrenia
• Mechanism of Action: Not completely elucidated; antagonizes dopamine D_2, serotonin 5-HT_{2A}, histamine H_1, and alpha$_1$ and alpha$_2$ adrenergic receptors
• Adverse effects: Most common: tachycardia, salivary hypersecretion, akathisia, dizziness, dystonia, extrapyramidal disorder, headache, somnolence, tremor, upper abdominal pain
• Contraindications: Contraindicated in patients with previous anaphylaxis or angioedema with risperidone or paliperidone. Not approved for the treatment of dementia-related psychosis – black box warning regarding increased mortality in elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs
• Precautions: potential for tardive dyskinesia, hyperglycemia, weight gain, hyperprolactinemia. Dose must be adjusted for renal insufficiency. Tablets cannot be crushed, chewed or divided. Pregnancy category C
<u>Automatic therapeutic substitution of risperidone for paliperidone:</u>
<table>
<tr><th colspan="2">Dosage equivalence of Paliperidone ER (Invega™)
versus
Risperidone (Risperdal™)</th></tr>
<tr><th>Paliperidone ER dose</th><th>Risperidone dose</th></tr>
<tr><td>3mg</td><td>2mg</td></tr>
<tr><td>6mg</td><td>4mg</td></tr>
<tr><td>9-12mg</td><td>6mg</td></tr>
</table></td></tr>
<tr><td>• SEVELAMER CARBONATE (RENVELA®)</td><td>SEVELAMER CARBONATE (RENVELA®) ADDED TO FORMULARY

(SEVELAMER HYDROCHLORIDE (RENAGEL®) REMOVED FROM FORMULARY)

AUTOMATIC SUBSTITUTION OF RENAGEL® TO RENVELA®</td><td>• Indication: The control of serum phosphorus in patients with chronic kidney disease on dialysis
• Mechanism of Action: Binds phosphate in the gastrointestinal tract, thereby decreasing phosphorus absorption
• Adverse effects: Likely similar to Renagel®, which include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, flatulence, and constipation
• Contraindications: In patients with hypophosphatemia or bowel obstruction
• Precautions: Safety has not been established in patients with a variety of gastrointestinal disorders (including dysphagia, swallowing disorders, severe GI motility disorders), or following major GI tract surgery. Like Renagel®, would be expected to bind some other medications (such as ciprofloxacin), therefore other medications should be administered at least 1 hour before or 3 hours after sevelamer. Pregnancy category C
<u>Automatic therapeutic substitution of Renvela® for Renagel®</u> at the same dose and frequency; MD will be contacted for Renagel® orders that utilize the 400 mg dose (e.g. 400 mg, 1200 mg, etc.), as Renvela® is only available as a 800 mg tablet, which cannot be split</td></tr>
</table>

• **NEDOCROMIL SODIUM INHALER (TILADE®)**	**REMOVED FROM FORMULARY (DISCONTINUED BY MANUFACTURER)**	
• **AUTOMATIC SUBSTITUTIONS**	• **Flurbiprofen (Ocufen®) automatically substituted <u>to</u> Ketoprofen (Acular®) at same dose and frequency** • **Preparation H® (Shark oil; 0% hydrocortisone)** **Analpram® (1% pramoxine, 1% hydrocortisone)** **Anusol HC® or Proctosol HC® (2.5% hydrocortisone cream)** } **Automatically substituted <u>to</u> Preparation H 1%®** • **Proctosol HC® (hydrocortisone 30 mg suppository) automatically substituted <u>to</u> hydrocortisone 25 mg suppository** • **During albumin 5% shortage <u>ONLY</u>:** o **Albumin 5% 250 ml -> Albumin 25% 50 ml over 15-30 minutes, followed by NS 250 ml over 60 minutes (unless otherwise specified by MD)** o **Albumin 5% 500 ml -> Albumin 25% 100 ml over 15-30 minutes, followed by NS 500 ml over 60 minutes (unless otherwise specified by MD)** • **During Comvax® shortage <u>ONLY</u>:** **Haemophilus B/Hepatitis B vaccine (Comvax®) automatically substituted <u>to</u> Hepatitis B (Recombivax HD®) + Haemophilus B (ActHIB®)** • **During Sodium Chloride tablet unavailability <u>ONLY</u>:** **Sodium chloride 1 gm PO substituted <u>to</u> Thermotabs® 2 tablets PO** **Sodium chloride 2 gm PO substituted <u>to</u> Thermotabs® 4 tablets PO** **Sodium chloride 3 gm PO substituted <u>to</u> Thermotabs® 6 tablets PO** ***(each Thermotab® tablet contains: 462 mg NaCl, 287 mg chloride (as KCl and NaCl) and 15 mg KCl)***	
• **RANOLAZINE (RANEXA®) DEAR DOCTOR LETTER**	• **Copy of letter will be placed in the Physician Orders Section of the medical chart** • **Letter will also be faxed to PMD's office if patient is being followed by a Teaching service** Ranozaline DDL	
• **BURST SUPPRESSION PHYSICIAN GUIDELINE** **(NOTE: THIS IS NOT A PHARMACY PROTOCOL)**	Burst Suppression MD Guideline	
• **2008 EMPIRIC TREATMENT RECOMMENDATIONS**	Empiric treatment recs 2008	
• **ANTIBIOTIC DOSING PER PHARMACY PROTOCOL (REVISION)**	antibitotic dosing protocol	
• **USE OF CARBAPENEMS IN PATIENTS WITH PENICILLIN ALLERGY** **PHYSICIAN GUIDELINE (NOTE: THIS IS NOT A PHARMACY PROTOCOL)**	**Restricted to Infectious Diseases as a 6-month test-of-change** B3D. PCN allergy and use of carbapenems (	

• **DISCONTINUE ANTIBIOTIC CONTINGENCY ORDERS**	**Antibiotic 'contingency orders" will not be accepted (exception: febrile/neutropenia order set #8994)** B3E. ABx contingency orders -
• **2007 MEDICATION SAFETY COLLABORATIVE ANNUAL REVIEW AND 2008 MEDICATION SAFETY COLLABORATIVE SAFETY INITIATIVES**	B5B. 2007 Med Safety annual review B5C. 2008 Medication Safety Ini
• **FDA ALERTS**	• **Abacavir (Ziagen®) and Didanosine (Videx®) – increased risk of myocardial infarction** B9E1. Abacavir & Didanosine FDA 03.0 • **Becaplermin (Regranex®) – increased risk of death from cancer in diabetic patients** B9E2. Becaplermin FDA 03.08.pdf • **Etanercept (Enbrel®) – serious infections, including bacterial sepsis, tuberculosis** B9E3. Enbrel FDA 03.08.pdf • **Insulin Inhalation Powder (Exubera®) – primary lung malignancies** B9E4. Exubera 04.08.pdf • **Montelukast (Singulair®) – behavior/mood changes, suicidality and suicide, serious congenital anomalies, spontaneous abortion** B9E5. Montelukast FDA 03.08.pdf • **Mycophenolate (Cellcept®) – progressive multifocal leukoencephalopathy** B9E6a. Mycophenolate 04.0 B9E6b. Mycophenolate FDA (

	• **Zanamivir (Relenza®) – delirium and abnormal behavior** B9E7. Relenza FDA 03.08.pdf
• **"PER PHARMACY" ORDERS**	• **Will be limited to medications for which a P&T Committee-approved pharmacy protocol exists (i.e. aminoglycosides, vancomycin, heparin, warfarin, argatroban, lepirudin, GCSF, erythropoietin, antiemetics in oncology, and antibiotics initial dosing). Pharmacists will be available to provide dosing assistance for other medications** • **MD must include indication to ensure dosing meets the intended goals of treatment**

Requests for full monographs or questions regarding this listing may be addressed to the Drug Information Center at **(310) 423-3784**

Angela Hirai Yang, PharmD — *Pharmacy Program Coordinator*
Hai Tran, PharmD — *Clinical Coordinator*
Rita Shane, PharmD, FASHP — *Director, Department of Pharmacy*